Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Bevacizumab (Avastin), Ranibizumab (Lucentis), Aflibercept (Eylea)
Intravitreal anti-VEGF · 1 trial · 1 indication
Measure the number of intravitreal anti VEGF injections from Month 1 through Month 12 following an intravitreal injection of AAVCAGsCD59 at Day 7
| Arm | Type | Description |
|---|---|---|
| AAVCAGsCD59 Treated Arm | EXPERIMENTAL | An anti-VEGF injection will be given at Day 0 followed by an intravitreal injection of AAVCAGsCD59 at Day 7. All eyes will then be treated with intravitreal anti-VEGF monthly as needed based on disease activity. |
| Name | Type | Description |
|---|---|---|
| Intravitreal anti-VEGF | DRUG | Intravitreal injection of anti-VEGF at Day 0 then monthly as needed |
| Intravitreal AAVCAGsCD59 | BIOLOGICAL | An intravitreal injection of AAVCAGsCD59 will occur at Day 7 once |
| Oral prednisolone | DRUG | A 7 day tapering dose of oral prednisone will be taken at Day 30 by all patients |
Inclusion Criteria: 1. Men or women 50 years of age or older. 2. Treatment naive Wet AMD with no evidence of subretinal fibrosis under the fovea. 3. Presence of intraretinal and/or subretinal fluid on OCT. 4. Best corrected visual acuity (BCVA) Snellen equivalent 20/25 to 20/400 in the study eye us...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 7 | PHASE3 | Surabgene Lomparvovec, RGX-314, ABBV-6628 |
| Ocular Therapeutix Inc | OCUL | 3 | PHASE3 | OTX-TKI |
| 4D Molecular Therapeutics, Inc. | FDMT | 3 | PHASE3 | 4D-150 |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE3 | Aflibercept, Pozelimab, Cemdisiran |
| Novartis AG Sponsored ADR | NVS | 5 | PHASE2 | Iptacopan, GT005, FWY003 |
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901 |
| Kodiak Sciences, Inc. | KOD | 1 | PHASE3 | Tarcocimab tedromer, Tabirafusp tedromer |
| Hoffmann-La Roche | RHHBY | 10 | PHASE3 | Ranibizumab, Susvimo, RO7965032, OpRegen, Faricimab |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | ONS-5010 |
| Adverum Biotechnologies, Inc. | ADVM | 4 | PHASE3 | Ixo-vec, ADVM-022 |
| Apellis Pharmaceuticals, Inc. | APLS | 1 | PHASE2 | APL-3007 |
| Amgen Inc. | AMGN | 1 | PHASE3 | ABP 938, Aflibercept |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-81201887 |
| Ocugen Inc | OCGN | 1 | PHASE3 | OCU410 |
| Alcon AG | ALC | 1 | PHASE1 | AR-14034 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE1 | SAR402663 |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-033 |
| Bayer | BAYRY | 2 | - | Aflibercept |
Intravitreal anti-VEGF is an investigational small molecule being developed for the treatment of Wet Age-related Macular Degeneration. It is administered intravitreally and is currently in Phase 1 clinical development. The drug is being studied to evaluate its safety and potential efficacy in patients with this condition.
Intravitreal anti-VEGF is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug is currently in Phase 1 clinical development for the treatment of Wet Age-related Macular Degeneration.
Intravitreal anti-VEGF is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 clinical trial has been completed to evaluate its use in patients with Wet Age-related Macular Degeneration.
Intravitreal anti-VEGF has one completed clinical trial, identified as NCT03585556, titled 'AAVCAGsCD59 for the Treatment of Wet AMD'. This Phase 1 trial enrolled 25 participants in the United States and was an uncontrolled, non-randomized study. The trial included patients aged 50 years and older with Wet Age-related Macular Degeneration.
Intravitreal anti-VEGF is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Wet Age-related Macular Degeneration. The drug has completed a Phase 1 clinical trial, but it remains under investigation and has not received regulatory approval.